U-251 MG
Marca : CLS Cell Lines Service
U-251 MG Cells
General information
Description | The U-251 MG cell line is a well-characterized human glioblastoma multiforme (GBM) cell line that is extensively used in neuro-oncology research. Derived originally from a 75-year-old Caucasian female, this cell line has been instrumental in the study of brain tumors, particularly in understanding the molecular and cellular mechanisms underlying malignant gliomas. The U-251 MG cells exhibit astrocytic properties, which are characteristic of their origin from astrocytes, the predominant cell type involved in GBM. Genetically, U-251 MG cells harbor mutations and alterations typical of high-grade astrocytomas, including mutations in the TP53 gene and loss of heterozygosity in chromosome 10, which encompasses the PTEN gene. These genetic traits contribute to the cell line?s utility in studying tumor suppressor gene functions and the cellular pathways involved in tumor progression and resistance. The cells are also known for their robust in vitro growth rates and ability to form tumors when xenografted into immunocompromised mice, making them a valuable model for in vivo studies of tumor growth, invasion, and therapy response. Furthermore, U-251 MG has been employed in a multitude of studies focusing on therapeutic approaches, including chemotherapy resistance, radiation therapy outcomes, and the evaluation of novel anticancer compounds. Its extensive use in translational research highlights its relevance in bridging basic neuroscientific discoveries with clinical applications, particularly in the development of targeted therapies for glioblastoma. |
---|---|
Organism | Human |
Tissue | Brain |
Disease | Astrocytoma |
Synonyms | U-251MG, U-251-MG, U-251_MG, U251-MG, U251MG, U-251, U251, U251n, U251N, 251 MG, 251MG |
Characteristics
Age | 75 years |
---|---|
Gender | Male |
Ethnicity | Caucasian |
Morphology | Epithelial-like |
Growth properties | Adherent |
Identifiers / Biosafety / Citation
Citation | U-251 MG (Cytion catalog number 300385) |
---|---|
Biosafety level | 1 |
Expression / Mutation
Protein expression | Expression of GFAP and vimentin |
---|---|
Tumorigenic | SMRV: Negative, as confirmed by Real-Time PCR |
Handling
Culture Medium | DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 1.5 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Passaging solution | Accutase |
Doubling time | 24 hours |
Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
Split ratio | A ratio of 1:3 to 1:5 is recommended |
Seeding density | 1 x 10^4 cells/cm^2 |
Fluid renewal | 2 to 3 times per week |
Freezing recovery | Fast, within 24 hours |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile | Amelogenin: x,y CSF1PO: 11,12 D13S317: 10,11 D16S539: 12 D5S818: 11,12 D7S820: 10,12 TH01: 9.3 TPOX: 8 vWA: 16,18 D3S1358: 16,17 D21S11: 29,30 D18S51: 13 Penta E: 7,10 Penta D: 10,12 D8S1179: 13,15 FGA: 21,25 |
HLA alleles | A*: 02:01:01 B*: 18:01:01 C*: 05:01:01 DRB1*: 03:01:01 DQA1*: 05:xx DQB1*: 02:01:01 DPB1*: 04:02:01 E: 01:03:01 |